Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
What’s Next For Cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura Expands Roginolisib Trials to the US
Industry Insight
iOnctura Enhances Board to Accelerate Growth and Innovation
Industry Insight
Addressing Drug Resistance in Non-Small Cell Lung Cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
All news
Data & publication
Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Press release
iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO
Data & publication
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T cell function and activity
Press release
iOnctura Expands Roginolisib Trials to the US, Advancing Multi-Indication Strategy in Oncology
Press coverage
Biotech TV – Interview with Catherine Pickering
Press coverage
OncLive – Early Activity With Roginolisib Supports Ongoing Phase 2 OCULE-01 Trial in Metastatic Uveal Melanoma
Press release
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
Data & publication
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Data & publication
A Randomised Phase II Study of Roginolisib in Patients With Advanced / Metastatic Ocular / Uveal Melanoma (OCULE-01)
Press release
iOnctura bolsters leadership team with new appointments
Press coverage
Pharma Boardroom – Interview with Catherine Pickering
Press release
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
Looking for media
resources?